 PALO ALTO, Calif., Aug. 19, 2021 GLOBE NEWSWIRE -- Scilex Holding Company SCILEX, a subsidiary of Sorrento Therapeutics, Inc. NASDAQ: SRNE, announced that, effective September 1, 2021, ZTlido lidocaine topical system 1.8 has been added to multiple formularies, including two national PBMs Pharmacy Benefit Managers, a national health plan and two regional health plans thereby expanding coverage by up to 33 million lives. ZTlido zee-tee-lie-doh is indicated for relief of pain associated with post-herpetic neuralgia PHN, also referred to as post-shingles pain. 